A Roundup of This Week's #CureFacts

California Gov. Gavin Newsom signed AB 1682 on Sept. 27, requiring large-group health plans to cover prescribed scalp cooling starting Jan. 1, 2027. Medi-Cal coverage is pending federal approval.

In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes.

In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.

In the phase 3 ASAC trial, daily aspirin did not lower the risk of colorectal cancer returning after treatment for liver metastases, and serious side effects were more common.

Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.

Challenge yourself after cancer by building healthier habits, strengthening relationships, managing stress and embracing new experiences for a healthier life.

Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.

The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.